Tag: GlobeNewswire

Former Source Electronics and Avnet executive Doug Adams joins CEO Bill Wentworth and VP Sales and Marketing Monty Reagan to lead Data I/O’s expansion into Programming-as-a-Service (PaaS) as the Company integrates recently acquired A&J Programming

REDMOND, Wash., Nov. 03, 2026 (GLOBE NEWSWIRE) — Data I/O Corporation (NASDAQ: DAIO), the leading global provider of data programming equipment, provisioning services and security provisioning for Flash-based microcontrollers, and high-density memory devices, today announced the appointment of Douglas Adams as SVP Global Services, Support and Quality.

The appointment reunites Mr. Adams with Data I/O President and CEO Bill Wentworth and Vice President of Sales and Marketing Monty Reagan. Together, these three key, senior executives led the growth of Source Electronics into the largest independent device programming services business in the world, founded by Mr. Wentworth in 1988, sold to HIG Capital in 2001 and then acquired in 2008 by Avnet Inc. “This executive team has well over 100 years of direct experience in device provisioning and has helped set industry best practices, guided by our corporate pillars of quality, execution, and industry-leading KPIs. Source Electronics became the largest provisioning services business worldwide,” said Bill Wentworth, CEO of Data I/O. “Together we are now pairing our services experience with the Data I/O brand, along with newly acquired V-TEK, Inc. and A&J Programming, Inc. to accelerate our services strategy. The acquisition diversifies our customer base, reducing our reliance on the automotive industry and adding new lines of revenue not related to capital expenditure cycles. There is significant revenue opportunity to unlock value within A&J’s existing customer base. A&J has built an outstanding reputation over the last several decades in Silicon Valley. With our new leadership team we will build on top of that value A&J has developed with focus and execution to align with customers’ supply chain needs.

“With Doug joining the team, Data I/O now brings the industry’s most recognized brand in programming solutions and the industry’s most proven programming services leadership team together under one roof. This combination forms the foundation for Data I/O’s entry into Programming-as-a-Service (PaaS) to deliver programming services regionally and globally. Doug has recently been a consultant for Data I/O preparing for the acquisition and connecting with team members. This preparation will allow us to get out of the gate quickly.”

The appointment of Doug Adams follows the completion of Data I/O’s October 21, 2026, transformational acquisition of V-TEK, Inc. and A&J Programming, Inc. (collectively, “V-TEK”), which is anticipated to double the Company’s revenue and expand Data I/O into new markets, including data centers, AI, photonics, industrial automation, medical, military, aerospace and defense. A&J’s service expertise gives Data I/O an established programming services operation and an experienced team, significantly accelerating the Company’s PaaS rollout. A&J Programming will continue to serve its customers as “A&J Programming, a Data I/O Company.”

Douglas Adams: Operational Leadership at Global Scale

Mr. Adams served as VP of Sales and Marketing for Source Electronics prior to becoming COO. Mr. Wentworth promoted Doug to Chief Operating Officer of Source Electronics after a partner buy-out, where Doug led the operations that made Source the largest independent programming services provider worldwide. After Source Electronics was acquired by Avnet, Messrs. Wentworth and Adams grew Avnet’s programming business by 50% in four years. In 2014, Mr. Wentworth left Avnet and Doug led global operations for logistics, programming services, and quality LPSQ worldwide. He oversaw operations of 13 global distribution centers, 8 regional programming centers and over 30 ISO 9001 quality certifications. During his tenure at Avnet, Mr. Adams expanded and led the build-out of programming services on a global scale, overseeing the opening of multiple new regional programming centers, while maintaining six sigma level quality and superior customer experience.

Entering PaaS – Onsite and Regional Programming Services

“We are not abandoning the capital equipment business in any way; quite the opposite. We are expanding the solutions available to all customers and supply chain partners,” said Mr. Wentworth. “Investments in the core business and striving to build the best solutions in the industry will benefit Data I/O’s current and future customers allowing them to buy both capital equipment and services. With A&J Programming now part of the NEW Data I/O, we have a programming services operation in place today, and Doug is the right leader to scale it, just as he did at Avnet. Growing software and services are a key part of our future growth plan. Customers will continue to have the option to purchase our programming solutions and deploy them in their factories and utilize our regional programming service centers to help manage peak demand spikes.”

“Programming services is an integral part of the customer’s supply chain. It is fundamentally an operations business: disciplined process control, quality focused, strong IT security, and centered around customer success,” said Doug Adams, SVP Global Services, Support and Quality of Data I/O. “Data I/O has the technology and the installed base to grow services from which customers can opt for an OpEx vs. CapEx. It’s simple: more options lead to more customer satisfaction.”

Mitch Jacobs, SVP of Manufacturing and former CEO of V-TEK, stated, “During my first trip with Doug to the A&J facility, it was immediately apparent his connection with the team and the excitement throughout the building. Doug’s knowledge of the services business and his reputation for driving disciplined execution and scaling operations to meet customers’ global requirements is precisely what we are all very excited about. A&J Programming gives us a strong starting point: an experienced team and a working services operation, backed by V-TEK’s handling and automation systems and Data I/O’s programming and security technology. Being able to provide our customers with this new option creates an environment where we can help our customers regarding supply chain or region.”

About Data I/O Corporation
Since 1972, Data I/O Corporation (NASDAQ: DAIO) has been the global leader in device programming. In 2026, Data I/O united three industry leaders with the transformational acquisition of V-TEK, Inc. and A&J Programming, Inc. The combination enables Data I/O to provide the world’s most comprehensive solutions to support the entire data provisioning supply chain.  These solutions include data programming and security provisioning, semiconductor handling automation for test, inspection and packaging, and Programming-as-a-Service. The Company serves customers in the automotive, industrial automation, data center, AI, photonics, medical, military, aerospace and defense, IoT, and consumer electronics markets. OEMs and manufacturers of any size can program, securely provision, test and package devices from early samples through high-volume production, using modular and customized systems and flexible service options. Data I/O’s solutions are backed by a portfolio of patents (dataio.com/Company/Patents) and a global network of distribution partners and support and service professionals, ensuring success for customers.

Learn more at www.dataio.com, www.vtekusa.com, and www.ajprogram.com.

Forward-Looking Statements

Safe Harbor/Forward Looking Statements and Disclosure Information
The Company cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements, including the benefits anticipated from the acquisition. Such forward-looking statements involve risks, assumptions and uncertainties. Statements in this news release may be construed as a prediction of future operations and performance or events are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those expressed or implied by such statements.

Forward-looking statement disclaimers also apply to the timing and contributions of acquisitions, acquisition synergies, the demand for the Company’s products, the impact from geopolitical conditions including any related international trade restrictions, and cybersecurity incidents and the possibility that the Company’s containment and remediation efforts may be unsuccessful or becomes a challenging force in maintaining market share. Factors that may impact the Company’s operations and finances include uncertainties as to the ability to record revenues based upon the timing of product deliveries, market acceptance of Edge AI, shipping availability, installations and acceptance, accrual of expenses, coronavirus or other business interruptions, changes in economic conditions, part shortages, business disruptions and other risks including those described in the Company’s 10-K, 10-Q and other periodic filings with the Securities and Exchange Commission (SEC), press releases and other communications.

Data I/O may use its website (www.dataio.com) and investor relations page (www.dataio.com/Company/Investor-Relations), its X account (@DataIO_Company), and its LinkedIn page (linkedin.com/company/data-io) to disclose material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors and other interested parties should monitor these sites, in addition to following Data I/O’s press releases, Securities and Exchange Commission (SEC) filings, public conference calls and public presentations/webcasts.

Media Contacts
Data I/O Corporation
Jennifer Higgins
Director Corporate Marketing
higginj@dataio.com

+1-425-867-6922

Investor Contact
Darrow Associates, Inc.
Jordan Darrow
jdarrow@darrowir.com
+1-631-766-4528

Earnings conference call to be held on November 13, 2026, at 8:30 a.m. Eastern Time

IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it will release its financial results for the third quarter ended September 30, 2026, before U.S. market open on November 13, 2026.

Management will host an earnings conference call on November 13, 2026, at 8:30 a.m. Eastern Time. A question-and-answer session with investors and analysts will follow the prepared remarks.

Please register in advance for the conference using the link provided below.

[https://zoom.us/webinar/register/WN_CLFqOL3XTourhX2qjAJnxw]

Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/

About SBC Medical Group Holdings Incorporated
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000^® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com

Product mini-site presents designs for customer reporting, private AI Q&A and agentic workflows; CogniAI integration would extend document processing

KUALA LUMPUR, Malaysia, Nov. 03, 2026 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today introduced BGLC 1Lab, its laboratory workflow product, and announced its initial launch as a controlled GeneMatrix-focused pilot at its MRNA Scientific Sdn. Bhd. subsidiary. A dedicated product mini-site is available at www.bionexusgenelab.com/1lab.

1Lab is designed to connect clinic orders, specimen reception, bench activity, scientific review and report delivery in one traceable record. The workflow design links each step to accountable staff and makes a test’s progress and exceptions visible.

“We are in a transition phase in our healthcare business, toward services that can integrate with increasingly autonomous AI. We believe an important part of AI’s next phase of growth will come from connecting advances in large language models with the data and workflows needed to deliver useful services. We are developing 1Lab around laboratory operations, customer reporting and private AI, with qualified professionals retaining responsibility for laboratory and clinical decisions.” Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.

Starting with GeneMatrix

BioNexus has built an enterprise version of GeneMatrix, the software behind its blood-based genomic screening, and completed internal workflow testing. The 1Lab pilot at MRNA Scientific’s laboratory in Penang, Malaysia, focuses on connecting that analysis with the surrounding operational workflow.

The pilot will evaluate traceability and staff review before wider deployment. Clinical release of GeneMatrix Enterprise remains subject to validation and applicable security, privacy, regulatory and management reviews.

Secure reporting and private AI Q&A

The reporting system is designed to give referring clinics and authorized customers secure web and mobile access to released laboratory reports. That design includes viewing and downloading the current report, clear identification of corrected versions and retention of the report history. Patient access would follow clinician review and the laboratory’s release policy.

Private AI Q&A is designed to help customers understand their own reports in plain language. The Q&A design grounds answers in the exact released report version and approved explanatory material, with supporting references and limits on questions those sources cannot answer. Clinical interpretation and follow-up remain with the clinician. Release of report Q&A remains subject to clinical review, validation and regulatory assessment.

Agentic AI under laboratory control

1Lab’s AI design starts with staff-requested assistance: reading requisitions, drafting clinic messages and retrieving approved procedures. Source checks and named-person review govern each draft. More autonomous agent workflows are a longer-term development direction; specimen acceptance, run decisions, result verification and report authorization remain with authorized staff.

1Lab’s private and sovereign AI design centers on institutional control over model operation, data processing and access. It covers local hardware and institutionally managed computing capacity. For Malaysian deployments, design requirements include domestic hosting of personal data and exclusion of laboratory and patient records from public AI services and shared-model training.

CogniAI integration

Following the anticipated closing of the previously announced Malaysian license agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) (“Ruanyun”), BioNexus intends to integrate Ruanyun’s CogniAI document-intelligence platform into 1Lab. CogniAI would provide document recognition, classification and extraction for 1Lab’s reading agents.

The document-processing integration would support GeneMatrix report-access and companion development; report Q&A requires separate source-grounding, validation and release controls.

The October 5, 2026 license agreement with Ruanyun remains subject to technology delivery, written acceptance, due diligence and required approvals. Commercial deployment can begin only after closing.

Connecting laboratories and clinics

MarketsandMarkets estimates the worldwide laboratory information management system market, which spans all industries and includes software, services and support, at US$3.26 billion in 2026 and projects US$5.84 billion by 2031.¹ Malaysia’s Ministry of Health records 214 licensed private hospitals and 11,067 registered private medical clinics as of December 31, 2024.² BioNexus sees an opportunity to connect laboratories and referring clinics through workflow, secure reporting and private AI, starting with its own pilot.

Initial availability is limited to the controlled MRNA Scientific pilot. Release beyond the pilot, including agent, API and patient features, is subject to development, validation and applicable approvals. The mini-site includes designs shown with demonstration data. Clinics, laboratories and potential partners can explore 1Lab at www.bionexusgenelab.com/1lab or contact sales@bionexusgenelab.com.

¹ MarketsandMarkets, “Laboratory Information Management System (LIMS) Market – Global Forecast to 2031,” September 2026.

² Ministry of Health Malaysia, Health Facts 2025.

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements include the 1Lab pilot and wider release; GeneMatrix integration and validation; agentic workflows, customer reporting, private AI Q&A and related access features; private and sovereign AI deployment; CogniAI delivery, acceptance, closing and integration; the transition toward services integrating with increasingly autonomous AI; management’s view of future AI growth; industry-market projections; and adoption and commercialization beyond MRNA Scientific.

Actual results may differ materially because of development and integration difficulties; AI output errors and model or host performance; validation, cybersecurity, privacy, data-residency and healthcare regulatory requirements; technology delivery, acceptance, due diligence and closing conditions; intellectual-property and third-party rights; implementation resources and funding; competition and customer adoption; and other risks in the Company’s latest Form 10-K, subsequent Forms 10-Q and other SEC filings. Third-party market estimates have not been independently verified by the Company and are subject to differing definitions and forecasting assumptions. The pilot does not establish clinical validation or assure commercial availability, customer contracts or revenue. Forward-looking statements speak only as of the date made. BioNexus undertakes no obligation to update them except as required by law.

Investor Relations and Corporate Communications

BioNexus Gene Lab Corp.
ir@bionexusgenelab.com

~TMTG to Release Third Quarter 2026 Results and Host Call on Monday, November 9, 2026~

SARASOTA, Fla. and HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) — Trump Media & Technology Group Corp. (“TMTG”) (Nasdaq, NYSE Texas: DJT) and TAE Technologies, Inc. (“TAE”), an innovator in advanced technology across fusion energy, power management and cancer therapy, announced the filing of a second amended registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the companies’ previously announced merger. This filing marks continued progress towards merger completion.

TMTG Third Quarter 2026 Earnings Call

In addition, TMTG announced today that it will host a conference call at 5:00 p.m. ET on Monday, November 9, 2026, to discuss its financial results for the quarter ended September 30, 2026. Financial results will be issued in a press release after market close, prior to the call.

Interim CEO Kevin McGurn and CFO Phillip Juhan will host the call and answer previously-submitted questions. Participants may submit a question for management consideration by emailing it to earnings@tmtgcorp.com prior to 4:30 p.m. ET on Monday, November 9, 2026.

Access to the live webcast and replay of the conference call will be available here and on TMTG’s Investor Relations website at https://ir.tmtgcorp.com/. Additionally, you may listen to the live webcast via Truth+ at https://truthplus.tv/ or on your preferred device via the Truth+ app. The dial-in number for the conference call is 877-524-8416 (toll-free) or +1 412-902-1028 (international). Attendees are encouraged to dial in 15 minutes prior to the start of the call.

An audio replay of the webcast will be available until Wednesday, December 9, 2026. Dial 877-660-6853 (toll-free) or 201-612-7415 (international) to listen.

About Trump Media & Technology Group Corp.

The mission of Trump Media is to end Big Tech’s assault on free speech by opening up the Internet and giving people their voices back. Trump Media operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations; Truth+, a TV streaming platform focusing on family friendly live TV channels and on-demand content; and Truth.Fi, a financial services and FinTech brand incorporating America First investment vehicles.

About TAE Technologies, Inc.

Founded in 1998, TAE Technologies’ mission is to develop and commercialize advanced technologies that solve the world’s most difficult scientific and engineering challenges. TAE’s north star is to deliver reliable, abundant, and clean fusion technology as a cost-competitive component of the future global energy supply. Fusion development serves as a forcing function, requiring TAE to develop technologies across a broad and deep spectrum of highly technical fields, with various commercial applications, including power solutions and life sciences. TAE’s Power Solutions (“TPS”) business unit applies fusion-derived, microsecond-scale power control to the challenges created by highly dynamic AI compute loads, through its flagship offering, TAE PowerFabric™. TAE’s Life Sciences (“TLS”) business unit set out to leverage TAE Technologies’ proprietary fusion-derived particle accelerator technology to achieve a step change in radiation therapy, improve the lives of patients and combat difficult-to-treat cancers using biologically-targeted boron neutron capture therapy (“BNCT”). For more information, visit tae.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including statements regarding the proposed Merger between TMTG and TAE, the anticipated timing and benefits of the transaction, TMTG’s and TAE’s future business plans, and TAE’s development and commercialization of fusion energy technology, including the Da Vinci prototype power plant. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the risk that the Merger may not be completed on the anticipated timeline or at all, including as a result of a failure to obtain required shareholder, stockholder or regulatory approvals or satisfy other closing conditions; the possibility that anticipated benefits of the Merger may not be realized; the significant capital required to develop and commercialize TAE’s fusion technology; the risk that TAE may be unable to successfully develop or commercialize a viable fusion reactor on its expected timeline or at all; and other risks and uncertainties described in TMTG’s filings with the SEC, including the Registration Statement and the risk factors described therein. TMTG and TAE undertake no obligation to update any forward-looking statements, except as required by law.

Important Information for Shareholders and Where to Find It

In connection with the proposed Merger, TMTG has filed the Registration Statement with the SEC, which includes a document that serves as a proxy statement of TMTG, a prospectus of TMTG and a consent solicitation statement of TAE (the “proxy statement/prospectus/consent solicitation statement”). The Registration Statement has not yet become effective. This press release is not a substitute for the Registration Statement, the definitive proxy statement/prospectus/consent solicitation statement or any other document that TMTG may file with the SEC in connection with the proposed Merger. INVESTORS AND SECURITY HOLDERS OF TMTG AND TAE ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TMTG, TAE, THE PROPOSED MERGER AND RELATED MATTERS. Shareholders will be able to obtain, free of charge, copies of the Registration Statement and, once available, the definitive proxy statement/prospectus/consent solicitation statement and other documents filed with the SEC by TMTG through the website maintained by the SEC at www.sec.gov, or from TMTG’s investor relations website at ir.tmtgcorp.com.

Participants in the Solicitation

TMTG, TAE and their respective executive officers, directors, other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from TMTG’s shareholders with respect to the proposed transaction. Information regarding the respective executive officers and directors of TMTG and TAE is set forth in the Registration Statement and the proxy statement/prospectus/consent solicitation statement contained therein initially filed with the SEC on September 30, 2026, as amended. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the effective Registration Statement and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Merger and is not a substitute for the proxy statement/prospectus/consent solicitation statement or any other document that TMTG may file with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investor Relations Contact

Shannon Devine (MZ Group | Partner, MZ North America)

Email: shannon.devine@mzgroup.us

Media Contact

press@tmtgcorp.com

ATHENS, Greece, Nov. 03, 2026 (GLOBE NEWSWIRE) — TEN Ltd. (NYSE: TEN) (“TEN” or the “Company”), a leading diversified tanker and LNG operator, announced that it will report financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the market in New York on Thursday, November 19, 2026.

That same day at 10:00 a.m. Eastern Time, TEN will host a conference call to review the results as well as the management’s outlook for the business. The call, which will be hosted by TEN’s senior management, may contain information beyond that which is included in the earnings press release.

Conference Call Details:
Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877-405-1226 (US Toll-Free Dial-In) or +1 201-689-7823 (US and Standard International Dial-In). Please quote “Tsakos” to the operator and/or conference ID 13763599.
Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Simultaneous Slides and Audio Webcast:
There will also be a live, and then archived, webcast of the conference call and accompanying slides, available through the Company’s website. To listen to the archived audio file, visit our website www.tenn.gr and click on Webcasts & Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

ABOUT TEN Ltd.
Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 80 vessels, totaling approx. 10.4 million dwt.

For further information, please contact:

Company
Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis / Markella Kara
+212 661 7566
ten@capitallink.com

Recognition reflects strengths in integrated external workforce programs supported by AI-enabled technology and advisory services

Facts at a Glance:

• Everest Group named KellyOCG an MSP Leader for the 12^th consecutive year, and a services procurement Leader for the eighth straight year.
• Everest Group cited the benefits of the KellyOCG integrated external workforce program and the unified enterprise talent management model at Kelly.
• Everest Group also highlighted investments by KellyOCG in the Sevayo^® workforce technology platform, including new AI, automation, and analytics features.

TROY, Mich., Nov. 03, 2026 (GLOBE NEWSWIRE) — KellyOCG^®, the outsourcing and consulting group of Kelly^® (Nasdaq: KELYA, KELYB), a global workforce strategy and solutions provider, has been named a Leader on Everest Group’s 2026 PEAK Matrix^® for both Contingent Workforce Management (CWM)/Managed Service Provider (MSP) and Services Procurement/Statement of Work (SOW). This marks the 12^th consecutive year KellyOCG has been positioned as an MSP Leader and the eighth straight year it has been named a services procurement Leader by Everest Group.

“Clients are asking for more than managed programs. They want one connected view of every talent channel, from contingent labor and SOW to direct sourcing and independent workers,” said Debra Timmerman, president, global MSP solutions, KellyOCG. “Being positioned as a Leader on both assessments reflects the work our team has done to bring those channels together under common governance, with our Sevayo^® workforce technology platform giving clients the insights to act on it.”

Everest Group’s PEAK Matrix^® provides an objective, data-driven assessment of global CWM/MSP and services procurement/SOW providers based on market impact, vision, and capability. Providers are assessed in seven categories: market adoption, portfolio mix, value delivered, scope of services offered, innovation and investments, delivery footprint, and vision and strategy. They are positioned as Leaders, Major Contenders, or Aspirants. The 2026 assessments evaluated 41 providers in CWM/MSP and 25 in services procurement/SOW, based on 12-month trailing deal activity through December 2025.

Everest Group noted that KellyOCG has adopted an integrated external workforce model, which brings contingent labor, services procurement, direct sourcing, independent contractor and freelancer management, and human cloud under a common framework. Everest Group also highlighted the strengths of the enterprise talent management approach that unifies contingent staffing, MSP, recruitment process outsourcing (RPO), and consulting under a single global structure.

KellyOCG continues to strengthen its Sevayo platform as the experience and orchestration layer across its contingent workforce management ecosystem, connecting vendor management systems, applicant tracking systems, procurement, analytics, and specialized technology platforms. Everest Group noted Sevayo’s analytics and prescriptive intelligence features that support unified analytics and natural language querying, along with Sevayo’s use of AI for conversational intake, workforce decision support, SOW validation, workforce classification, and compliance assessment.

In services procurement/SOW, Everest Group pointed to the modular delivery and dedicated procurement expertise at KellyOCG, spanning SOW administration, sourcing, supplier selection and negotiation, benchmarking, category strategy, and procurement advisory. These services are available as stand-alone modules or within broader end-to-end programs.

“KellyOCG is evolving its CWM approach around external workforce orchestration, bringing together multiple talent channels, technology, and advisory capabilities within a robust and integrated operating model,” said Lokesh Goyal, vice president, Everest Group. “KellyOCG has built comprehensive services procurement capabilities, supported by its procurement and category expertise, modular service offerings, and experience across the SOW lifecycle.”

About KellyOCG^®
KellyOCG connects companies with the talented people they need to fuel and grow their business through our unrivaled global talent supply chain and leading workforce offerings including managed service provider (MSP), recruitment process outsourcing (RPO), and total talent solutions. We combine decades of people industry experience with proprietary insights and a continued focus on technology to produce world-class programs that meet an organization’s unique workforce needs and can start it on its journey to total talent management. Our ability to anticipate what’s next for talent solutions drives us to challenge the status quo, making us a trusted partner for our global client portfolio, which spans leading industries across North America, APAC, and EMEA.

About Kelly^®
At Kelly^® (Nasdaq: KELYA, KELYB), we don’t just understand the future of work, we’re defining it. For over 80 years, we’ve sourced specialized talent, built agile workforces, and shaped growth strategies for employers around the world. Today, our recruiting, outsourcing, and consulting services provide the talent and solutions organizations need to move faster and grow smarter. We deliver meaningful impact by connecting people to work that enriches their lives, and companies to people who drive innovation and growth. Each year, we place more than 375,000 job seekers in new roles spanning science, engineering, technology, telecom, education, manufacturing, and more.

About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group’s PEAK Matrix^® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix^® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix^® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix^® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix^® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix^® Reports.

Media Contact
Christian Taske
248-561-8823
christian.taske@kellyservices.com

This press release was published by a CLEAR® Verified individual.

Non-binding term sheet sets out the principal terms for a potential long-term Enhanced Use Lease of up to 75 years to develop domestic dysprosium and terbium processing on a U.S. defense installation

EUCLID, Ohio, Nov. 03, 2026 (GLOBE NEWSWIRE) — REalloys Inc. (NASDAQ: ALOY) (“REalloys” or the “Company”), a U.S.-based rare earth minerals and materials company building a vertically integrated North American “mine-to-magnet” supply chain, today announced that a subsidiary of REalloys and the U.S. Department of the Army (“Army”) have executed a non-binding term sheet setting out the principal commercial terms for a potential Enhanced Use Lease (“EUL”) to develop a heavy rare earth processing facility at Tooele Army Depot in Utah. Other than certain customary provisions, the term sheet is non-binding, and there can be no assurance that a definitive EUL will be executed.

The term sheet follows the Army’s June 25, 2026 selection of REalloys as the solicitation awardee enabling exclusive negotiations under its Strategic Capital Initiatives. It contemplates development of the facility on approximately 200 acres at Tooele Army Depot. The facility would process and refine target critical minerals, including dysprosium (“Dy”) and terbium (“Tb”), the heavy rare earth elements used in, among other things, high-temperature permanent magnets for precision-guided munitions, electric motors, sonar, radar and other defense systems.

Under the proposed framework, REalloys would develop, finance, build, operate and ultimately decommission the facility while the United States would retain title to the land.

HIGHLIGHTS

• Long-Term Site Tenure: Initial 50-year lease term with one 25-year renewal option, subject to specified conditions, including Army consent, providing the potential for up to 75 years of operating tenure.
• Army Right of First Offer: The Army would have a right of first offer to purchase product from the facility, subject to applicable federal law and procurement requirements. The Army is not obligated to purchase any product.
• Strategic U.S. Defense Installation: The proposed facility would be developed on approximately 200 acres at Tooele Army Depot, establishing domestic heavy rare earth processing within an existing
• U.S. defense installation.
• Defense-Critical Scope: The facility would process and refine target critical minerals, including Dy and Tb. Additional rare earth elements may be processed at the site in the future as mutually agreed in writing.
• Project Consideration: Project consideration would consist of annual base rent at fair market value beginning at lease commencement, plus participation rent beginning upon commercial operations, with terms to be agreed in the EUL.

Leonard Sternheim, Chief Executive Officer of REalloys, commented:
“Agreeing to this term sheet with the U.S. Army is an important step for our Tooele project as we work toward a long-term lease. Dysprosium and terbium are essential to the magnets in America’s most advanced defense systems, and almost all of that processing still happens overseas. We believe this framework would provide long-duration site access on a U.S. defense installation and a structure to facilitate continued cooperation between REalloys and the Army. We look forward to working with the Army toward a definitive lease.”

General Jack Keane (U.S. Army, Ret.), Director of REalloys, commented:
“For too long, the United States has depended on adversaries and others for the materials inside its most advanced defense technology and China has made clear it is prepared to use that dependence as leverage. Dysprosium and terbium sit at the center of that vulnerability. Our ability to deter conflict, and to prevail if deterrence fails, depends on producing munitions and weapons systems at scale, and that requires supply chains we control. This term sheet is an important step toward bringing heavy rare earth processing onto a U.S. defense installation. “

Dr. Jeff Waksman, Principal Deputy Assistant Secretary of the Army for Installations, Energy and Environment, commented:
“Rare earth processing is a known national security vulnerability, with China specifically holding a near 100% global monopoly on dysprosium and terbium. Leveraging our legal authorities and land, the U.S. Army is able to help nurture and expedite the growth of critical minerals industrial base which equips and sustains America’s Soldiers without putting any taxpayer dollars at risk.”

NEXT STEPS
REalloys and the Army will now work to complete the remaining project-development conditions and negotiate the definitive EUL.

Execution of the EUL remains subject to conditions, including agreement on the fair market value of base rent and the participation rent methodology, Army acceptance of REalloys’ development plan, completion of environmental reviews and permitting activities, satisfactory completion of a foreign ownership, control or influence review, securing project financing and REalloys Board approval, as well as applicable Army determinations and Congressional notifications. If the conditions are not satisfied or waived within 18 months, either party may terminate the term sheet.

REalloys continues to advance its broader mine-to-magnet platform in parallel, including its strategic relationship with the Saskatchewan Research Council and its rare earth metallization development activities.

About REalloys Inc.
REalloys Inc. (NASDAQ: ALOY) is a U.S.-based rare earth materials company executing a mine-to-magnet strategy across upstream feedstock, midstream separation and metallization, and downstream magnet manufacturing. REalloys is focused on delivering qualified, allied-nation rare earth metals and alloys including dysprosium, terbium, praseodymium and neodymium to the U.S. Department of War, the U.S. Department of Energy, NASA, the U.S. Defense Industrial Base, and the broader U.S. Organic Industrial Base.
For more information, please visit www.REalloys.com or email InvestInAmerica@REalloys.com.

About the U.S. Army Strategic Capital Initiatives (SCI)
The Army’s Strategic Capital Initiatives partner with the private sector to accelerate enterprise-wide modernization, including using Enhanced Use Leases to establish domestic critical-mineral processing on Army installations. For more information, visit www.army.mil/sci.

Safe Harbor Statement and Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the proposed EUL at Tooele Army Depot and the terms set out in the term sheet; the anticipated negotiation, timing and execution of a definitive EUL; the satisfaction of conditions precedent to execution of the EUL, including agreement on fair market value base rent and participation rent, Army acceptance of REalloys’ development plan, completion of environmental reviews (including under the National Environmental Policy Act), permitting, foreign ownership, control or influence review, project financing, REalloys Board approval, and applicable Army determinations and Congressional notifications; the anticipated lease term and any renewal; the Army’s right of first offer; the anticipated development, financing, construction, operation and decommissioning of the proposed facility; the processing of dysprosium, terbium and other rare earth elements at the facility; and REalloys’ broader mine-to-magnet strategy. These forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve significant risks and uncertainties.

Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including, but not limited to: the non-binding nature of the term sheet (other than certain customary provisions); the possibility that the parties will be unable to agree on the terms of a definitive EUL, including base rent and participation rent, on acceptable terms or at all; the failure to satisfy, or delays in satisfying, the conditions precedent to execution of the EUL, including the right of either party to terminate the term sheet if such conditions are not satisfied or waived within 18 months; the outcome and timing of environmental reviews, permitting and other governmental approvals; the Army’s discretion with respect to approvals, consents and renewal of the EUL; the availability of project financing and other capital on acceptable terms; construction, commissioning and operational risks; the availability, quality and cost of rare earth feedstocks; fluctuations in rare earth prices and customer demand; the fact that the Army’s right of first offer does not obligate the Army to purchase any product; changes in applicable laws, regulations, government policies, appropriations or administration priorities; and other risks described from time to time in REalloys’ filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings.

There can be no assurance that a definitive EUL will be executed within the anticipated timeframe or at all, that any EUL will be on the terms described in this press release, or that the proposed facility will be developed, financed, constructed or operated as currently contemplated. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, REalloys undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Disclosure Information
REalloys uses and intends to continue using its investor website at www.REalloys.com as a means of disclosing material non-public information and for complying with Regulation FD. Investors should monitor this site, along with the Company’s press releases, SEC filings, public conference calls, and webcasts.

Media & Investor Contact
IR and Communications, REalloys
InvestInAmerica@REalloys.com
www.realloys.com

• Four presentations highlight BriaCell’s Bria-OTS+™ cellular immunotherapy platform and BriaPro’s CD80-based immunotherapy programs
• In vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer models
• BriaPro data describes BP-80 tolerability in nonhuman primates and engineered CD80 constructs with enhanced PD-L1 binding

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced four preclinical research presentations at the Society for Immunotherapy of Cancer (SITC) 41^th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

The presentations cover BriaCell’s personalized off-the-shelf immunotherapy platform, Bria-OTS+, and three BriaPro research programs: BP-80, a soluble CD80-Fc fusion protein; TILsRx-001, a tumor-targeted CD80-based checkpoint inhibitor; and engineered CD80 variants with altered immune receptor binding.

“The Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing in laboratory models spanning breast, prostate and lung cancers,” said Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “These findings support continued investigation of the platform, including how its immune responses may translate into clinical activity, potentially providing more durable and effective cancer immunotherapies.”

“The four presentations provide additional preclinical data supporting our cellular and protein-based immunotherapy research,” stated William V. Williams, MD, BriaCell’s President and CEO. “We are advancing the clinical evaluation of our Bria-OTS+ programs while continuing preclinical development of BriaPro’s candidates.”

Presentation abstract summaries are listed below.

BriaCell

Title: A Multifaceted Genetically Engineered Whole-Cell Vaccine Platform Generates Potent, Broad, Persistent, and Effector-Centric Anti-Tumor Immunity Across Multiple Cancer Indications
Abstract Number: 863
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026

Summary: Bria-OTS+ is a modular allogeneic whole-cell vaccine platform engineered to combine tumor-derived antigens, immune-stimulatory cytokines, co-stimulatory molecules, and diverse HLA antigens. Bria-OTS+ activated innate and adaptive immune cells, including dendritic, NK, NKT, CD4+ T, and CD8+ T cells, represented by increased activation markers, cytokine production, proliferation, and cytotoxicity. Bria-OTS+ also induced immune activation in PBMCs obtained from cancer patients, extending these findings beyond healthy-donor models.

In vitro studies showed that Bria-OTS+ stimulated innate and adaptive immune responses, broad tumor recognition, sustained cytotoxicity, and memory-like responses across breast, prostate, and lung cancer models, supporting its potential as a broadly applicable cancer immunotherapy platform.

BriaPro

Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
Abstract Number: 404
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026

Summary: BP-80 is a soluble CD80-Fc fusion protein incorporating the full wild-type CD80 extracellular domain, designed to promote T cell activation through CD28 co-stimulation and counteracting CTLA-4-mediated inhibition. Its Fc region contains L234A/L235A (LALA) mutations to reduce antibody-dependent effector functions. In cell-based assays, BP-80 demonstrated CD28 co-stimulatory activity and counteracted CTLA-4-mediated inhibition, with activity dependent on Fc receptor engagement and anti-Fc antibody-based crosslinking, respectively. In cynomolgus monkeys, BP-80 demonstrated a no observed effect level (NOEL) of 50 mg/kg/day and a half-life ranging from 8.08 to 8.92 hours.

Title: Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes
Abstract Number: 405
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026

Summary: TILsRx-001 is a tumor-targeted, tetravalent immune checkpoint inhibitor comprising an engineered CD80 extracellular domain with enhanced PD-L1 affinity and an anti-B7-H3 single-chain variable fragment (scFv) for tumor targeting. In a cell-based study, TILsRx-001 antagonized the immune inhibitory effect of PD-L1 expressed on cells co-expressing B7-H3, supporting further investigation of targeted checkpoint inhibition to enhance tumor-infiltrating lymphocyte (TIL) activity.

Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28
Abstract Number: 406
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026

Summary: CD80 (B7-1) regulates T cell activity through interactions with CD28, PD-L1, and CTLA-4. Structure-guided protein engineering identified CD80 variants with increased PD-L1 binding affinity and minimal effect on CD28 affinity, a potential approach to limiting excessive T cell stimulation. One variant demonstrated more than 130-fold stronger PD-L1 binding than wild-type CD80 (0.23 µM versus >30 µM). Another mutation increased CTLA-4 affinity approximately fivefold while preserving CD28 affinity. These findings support further development of engineered CD80 proteins for cancer immunotherapy.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

About BriaPro Therapeutics Corp.

BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell and BriaPro presenting posters at the SITC 2026 Annual Meeting, and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

ATLANTA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Gray Media has promoted Jaime Eskridge to General Manager of WLFI, Gray’s CBS affiliate in Lafayette, Indiana, effective November 2.

Jaime first joined WLFI in 2015 as Digital Sales Director and was promoted to Sales Manager in 2016.   From 2022 to 2025, Jaime served on the Allen Media corporate digital team, driving digital sales strategies and growth initiatives across 22 television stations. At the end of 2025, Jaime returned home to WLFI and has served as the interim General Manager for the last several months.

An Indiana native originally from LaPorte, Jaime is a proud alumna of Indiana University Bloomington. She serves on the Greater Lafayette Salvation Army Advisory Board.

 

About Gray Media:

Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Gray Contact:

Sandy Breland, Executive Vice President, Chief Operating Officer, 404-266-8333

# # #

• New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session

COPENHAGEN, Denmark, November 3, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.

The new data includes analysis of broad systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses. It will be presented in both an oral and poster session at the SITC meeting.

To further understand the immunological mechanisms underlying EVX-01 activity, we performed longitudinal immune profiling of treated patients. The analyses included characterization of vaccine-specific T-cell responses together with profiling of systemic, treatment-associated immune responses. These data provide insights into the magnitude, quality, durability, and systemic impact of EVX-01-induced immunity in advanced melanoma.

SITC oral and poster presentation details:

• Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
• Abstract#: 502

Oral presentation:

• Session:  105b: Rapid Oral – Clinical 1
• Location: Phoenix Convention Center, West Building-300 Level – 301BC
• Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20.30-21.30 CET
• Presenter:  Mads Lausen, Senior Scientist at Evaxion

Poster presentation:

• Session: Poster Session
• Location: Phoenix Convention Center, North Building-Lower Level – Exhibition Halls 4-6
• Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
• Presenter:  Mads Lausen, Senior Scientist at Evaxion

About the phase 2 trial
The phase 2 trial investigated EVX-01 in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial received a unique vaccine designed with Evaxion’s AI-Immunology™ prediction platform and manufactured based on their individual biology.

At two-year follow-up, the trial demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Clinical and T-cell responses were sustained at three-year follow-up. 89% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). In the third year, a subset of patients received EVX-01 as stand-alone therapy. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system by mounting a targeted response against tumor-specific neoantigens.

Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.